AGLE
Price:
$12.01
Market Cap:
$5.04B
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating human enzyme therapies for rare metabolic diseases. Their leading candidate, pegzilarginase, a recombinant human Arginase 1, is currently in the pivotal Phase III PEACE trial to assess its safety and effectiveness for treating Arginase 1 deficiency. Furthermore, the company is developing AGLE-177, a polyethylene glycol modified enzyme, which is progressing through Phase I/II clinical trials for homocystinuria. Their early-stage pipeline includes AGLE-325 for cystinuria, along with other ongoing research initiatives. Founded in 2013, the company was initially known as Aeglea BioTherapeutics Holdings, LLC...[Read more]
Industry
Biotechnology
IPO Date
2016-04-07
Stock Exchange
NASDAQ
Ticker
AGLE
According to Aeglea BioTherapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.16. This represents a change of -99.55% compared to the average of -35.71 of the last 4 quarters.
The mean historical PE Ratio of Aeglea BioTherapeutics, Inc. over the last ten years is -10.07. The current -0.16 PE Ratio has changed 60.78% with respect to the historical average. Over the past ten years (40 quarters), AGLE's PE Ratio was at its highest in in the June 2023 quarter at -0.05. The PE Ratio was at its lowest in in the March 2026 quarter at -63.24.
Average
-10.07
Median
-3.32
Minimum
-73.04
Maximum
-0.44
Discovering the peaks and valleys of Aeglea BioTherapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.29%
Maximum Annual PE Ratio = -0.44
Minimum Annual Increase = -90.47%
Minimum Annual PE Ratio = -73.04
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -73.04 | 1.29% |
| 2024 | -5.26 | 1.10% |
| 2023 | -0.44 | -3.18% |
| 2022 | -0.45 | -90.47% |
| 2021 | -4.75 | -8.60% |
| 2020 | -5.19 | 66.46% |
| 2019 | -3.12 | -11.30% |
| 2018 | -3.52 | 17.03% |
| 2017 | -3.00 | 53.08% |
| 2016 | -1.96 | -80.14% |
The current PE Ratio of Aeglea BioTherapeutics, Inc. (AGLE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-26.25
5-year avg
-16.79
10-year avg
-10.07
Aeglea BioTherapeutics, Inc.’s PE Ratio is greater than bluebird bio, Inc. (-0.84), greater than GreenLight Biosciences Holdings (-0.24), less than Lunai Bioworks Inc. (-0.07), greater than AlloVir, Inc. (-2.35), greater than Rein Therapeutics Inc. (-0.57), less than ERYTECH Pharma S.A. (-0.02), greater than Kronos Bio, Inc. (-1.57), less than Magenta Therapeutics, Inc. (-0.02), greater than TCR2 Therapeutics Inc. (-0.38), greater than Pluristem Therapeutics Inc. (-0.99),
| Company | PE Ratio | Market cap |
|---|---|---|
| -0.84 | $48.67M | |
| -0.24 | $45.43M | |
| -0.07 | $32.92M | |
| -2.35 | $49.48M | |
| -0.57 | $26.42M | |
| -0.02 | $47.38M | |
| -1.57 | $53.65M | |
| -0.02 | $42.44M | |
| -0.38 | $58.11M | |
| -0.99 | $40.85M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aeglea BioTherapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aeglea BioTherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Aeglea BioTherapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Aeglea BioTherapeutics, Inc. (AGLE)?
What is the highest PE Ratio for Aeglea BioTherapeutics, Inc. (AGLE)?
What is the 3-year average PE Ratio for Aeglea BioTherapeutics, Inc. (AGLE)?
What is the 5-year average PE Ratio for Aeglea BioTherapeutics, Inc. (AGLE)?
How does the current PE Ratio for Aeglea BioTherapeutics, Inc. (AGLE) compare to its historical average?